Drugmakers raised the list prices of more than 800 prescription drugs for blood pressure, cancer and other conditions by a ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $808.17 which represents a slight increase of $22.76 or 2.90% from the prior close of $785.41. The stock opened at $780.91 and ...

RALEIGH – The North Carolina Rural Economic Development Center has received a grant of $6.38 million from Lilly Endowment Inc ...

Minnesotans prescribed insulin won’t pay more than $35 per month for it, after the conclusion of a lawsuit against three ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

IUSG follows a growth-oriented strategy but lags behind peers due to conservative allocations in key growth sectors like ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin.